Valeant Pharma's (VRX) Proposed Credit Amendment Will Improve Liquidity Position - Moody's
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Moody's Investors Service commented that a proposed amendment to Valeant Pharmaceutical International Inc.'s (NYSE: VRX) credit agreement will improve its liquidity position due to increased cushion under financial maintenance covenants. There is no impact on Valeant's ratings including the B2 Corporate Family Rating or the negative rating outlook.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Norfolk Southern (NSC) Ratings Affirmed by Moody's; Outlook Remains Stable
- Deutsche Bank Downgrades MGM Growth Properties (MGP) to Hold
- S&P Downgrades Rowan Cos. (RDC) to 'B+'; Outlook is Stable
Create E-mail Alert Related CategoriesCredit Ratings
Related EntitiesMoody's Investors Service
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!